پیوندهای مفید
آمار
| تعداد نشریات | 20 |
| تعداد شمارهها | 1,149 |
| تعداد مقالات | 10,518 |
| تعداد مشاهده مقاله | 45,416,269 |
| تعداد دریافت فایل اصل مقاله | 11,292,120 |
IL-35 Serum Levels in Bladder Cancer Patients: An Analytical Cross-sectional Study | ||
| Middle East Journal of Cancer | ||
| مقاله 5، دوره 9، شماره 4، دی 2018، صفحه 295-299 اصل مقاله (203.81 K) | ||
| نوع مقاله: Original Article(s) | ||
| شناسه دیجیتال (DOI): 10.30476/mejc.2018.42141 | ||
| نویسندگان | ||
| Ali Ariafar1؛ Sabereh Davari2؛ Shabnam Abtahi2؛ Abbas Ghaderi* 2 | ||
| 1Urology-Oncology Research Center, Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran | ||
| 2Shiraz Institute for Cancer Research, School of Medicine Shiraz University of Medical Sciences, Shiraz, Iran | ||
| چکیده | ||
| Background: Bladder cancer is a prevalent disease with significant health care costs and high rates of recurrence. Results from numerous studies to associate bladder cancer with serum biomarkers have been analyzed for prognostic indicators, or to develop agents for diagnostic and therapeutic applications. Interleukin-35 is a suppressive cytokine that has a role in tumor immunity as a regulatory cytokine by suppressing T cell anticancer responses. Methods: In the present study, we have investigated interleukin-35 serum levels in bladder cancer patients by ELISA, and compared these levels with a healthy comparison group, as well as among different clinicopathological subgroups.Results: We observed no difference in serum levels of interleukin-35 in bladder cancer patients and healthy controls; however, bladder cancer patients diagnosed at lower stages (0a, I, II) had significantly higher levels of interleukin-35 in their sera compared to high stage (III, IV) patients (P=0.018).Conclusion: Our results could indicate that interleukin-35 has no significant role in bladder cancer pathogenesis and progression. Interleukin-35 might not be a valuable biomarker for diagnosis or assessment of bladder cancer progression in clinical settings. However, further studies are needed in order to reach a definitive conclusion. | ||
| مراجع | ||
|
1. Morales A, Eidinger D. Bacillus Calmette-Guerin in the treatment of adenocarcinoma of the kidney. J Urol. 1976;115(4):377-80. 2. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27(3):289-93. 3. Letašiová S, Medve'ová A, Šovčíková A, Dušinská M, Volkovová K, Mosoiu C, et al. Bladder cancer, a review of the environmental risk factors. Environ Health. 2012;11 Suppl 1:S11. 4. Lee SJ, Lee EJ, Kim SK, Jeong P, Cho YH, Yun SJ, et al. Identification of pro-inflammatory cytokines associated with muscle invasive bladder cancer; the roles of IL-5, IL-20, and IL-28A. PLoS One. 2012;7(9):e40267. 5. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450(7169):566-9. 6. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol. 2010;11(12):1093-101. 7. Wang RX, Yu CR, Dambuza IM, Mahdi RM, Dolinska MB, Sergeev YV, et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med. 2014;20(6):633-41. 8. Wang Z, Liu JQ, Liu Z, Shen R, Zhang G, Xu J, et al. Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol. 2013;190(5):2415-23. 9. Jin P, Ren H, Sun W, Xin W, Zhang H, Hao J. Circulating IL-35 in pancreatic ductal adenocarcinoma patients. Hum Immunol. 2014;75(1):29-33. 10. Nicholl MB, Ledgewood CL, Chen XH, Bai Q, Qin CL, Cook KM, et al. IL-35 promotes pancreas cancer growth through enhancement of proliferation and inhibition of apoptosis: Evidence for a role as an autocrine growth factor. Cytokine. 2014;70(2):126-33. 11. Huang C, Li N, Li Z, Chang A, Chen Y, Zhao T, et al. Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression. Nat Commun. 2017;8:14035. 12. Fan YG, Zhai JM, Wang W, Feng B, Yao GL, An YH, et al. IL-35 over-expression is associated with genesis of gastric cancer. Asian Pac J Cancer Prev. 2015;16(7):2845-9. 13. Z Zeng JC, Zhang Z, Li TY, Liang YF, Wang HM, Bao JJ, et al. Assessing the role of IL-35 in colorectal cancer progression and prognosis. Int J Clin Exp Pathol. 2013;6(9):1806-16. 14. Zhou C, Zhang J, Chen Y, Wang H, Hou J. Interleukin-35 as a predictor of prostate cancer in patients undergoing initial prostate biopsy. Onco Targets Ther. 2017;10:3485-3491. 15. Chen G, Liang Y, Guan X, Chen H, Liu Q, Lin B, et al. Circulating low IL-23: IL-35 cytokine ratio promotes progression associated with poor prognosisin breast cancer. Am J Transl Res. 2016;8(5):2255-64. 16. Wu W, Jiang H, Li Y, Yan MX. IL-35 expression is increased in laryngeal squamous cell carcinoma and in the peripheral blood of patients. Oncol Lett. 2017;13(5):3303-8. 17. Wu H, Li P, Shao N, Ma J, Ji M, Sun X, et al. Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-beta in acute myeloid leukemia. Oncol Lett. 2012;3(5):1119-23. 18. Fu YP, Yi Y, Cai XY, Sun J, Ni XC, He HW, et al. Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection. Br J Cancer. 2016;114(7):767-76. 19. Gu X, Tian T, Zhang B, Liu Y, Yuan C, Shao L, et al. Elevated plasma interleukin-35 levels predict poor prognosis in patients with non-small cell lung cancer. Tumour Biol. 2015;36(4):2651-6. 20. Turnis ME, Sawant DV, Szymczak-Workman AL, Andrews LP, Delgoffe GM, Yano H, et al. Interleukin-35 limits anti-tumor immunity. Immunity. 2016;44(2):316-29. 21. Cheng L, Montironi R, Davidson DD, Lopez-Beltran A. Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol. 2009;22 Suppl 2:S70-95. 22. Comperat E, Varinot J. Immunochemical and molecular assessment of urothelial neoplasms and aspects of the 2016 World Health Organization classification. Histopathology. 2016;69(5):717-26. 23. Huang A, Cheng L, He M, Nie J, Wang J, Jiang K. Interleukin-35 on B cell and T cell induction and regulation. J Inflamm (Lond). 2017;14:16. 24. Jin L, Xu X, Ye B, Pan M, Shi Z, Hu Y. Elevated serum interleukin-35 levels correlate with poor prognosis in patients with clear cell renal cell carcinoma. Int J Clin Exp Med. 2015;8(10):18861-6. 25. Huang C, Li N, Li Z, Chang A, Chen Y, Zhao T, et al. Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression. Nat Commun. 2017;8:14035. 26. Wang K, Gong H, Chai R, Yuan H, Chen Y, Liu J. Aberrant frequency of IL-35 producing B cells in colorectal cancer patients. Cytokine. 2017. pii: S1043-4666(17): 30316-2. 27. Lu Y, Yuan Y. Serum level of interleukin-17 and interleukin-35 as a biomarker for diagnosis of thyroid cancer. J Cancer Res Ther. 2015;11(6):C209-C11. 28. Long J, Zhang X, Wen M, Kong Q, Lv Z, An Y, et al. IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells. Biochem Biophys Res Commun. 2013;430(1):364-9. | ||
|
آمار تعداد مشاهده مقاله: 3,417 تعداد دریافت فایل اصل مقاله: 1,520 |
||